VB-111: Additional Phase I/II data

Data from 46 patients with recurrent GBM in a 2-stage, dose-escalation, open-label, U.S. and Israeli Phase I/II trial showed that IV VB-111 plus Avastin bevacizumab led to a median OS of 504 days vs. 235 days for Avastin alone. In the first stage of the trial, all patients received VB-111 alone. Upon disease progression, patients received VB-111 plus Avastin or Avastin alone. In 15 evaluable patients who received VB-111 plus Avastin, there were 3 partial responses and 12 cases of stable disease. VB-111 was well tolerated both as monotherapy and in combination with Avastin. Data were presented at the Society for Neuro-Oncology meeting in Miami. VBL previously reported data from the trial (see BioCentury, June 24, 2013). ...